Active Recombinant Human IL33 protein

• Cat.No.: IL33-215H
• Product Overview: Recombinant Human IL33(Ser 112-Thr 270) fused with an initial Met at the N-terminus was expressed in E. coli.

Specification

• Description: Interleukin 33 (IL-33), also known as DVS27 or NF-HEV (Nuclear Factor from High Endothelial enules), is a proinflammatory protein and a chromatin-associated cytokine of the IL-1 family with high sequence and structural similarity to IL-1 and IL-18. IL-33 protein is expressed highly and rather selectively by high endothelial venule endothelial cells (HEVECs) in human tonsils, Peyers's patches, and lymph nodes. IL-33 protein has transcriptional regulatory properties, and the researches suggested that IL-33 is a dual-function protein that might act both as a cytokine and as an intracellular nuclear factor. As a type 2 cytokines, IL-33 protein also play a pivotal role in helminthic infection and allergic disorders.
• Source: E. coli
• Species: Human
• Predicted N Terminal: Met
• Form: Lyophilized from sterile PBS, pH 7.4.
• Bio-activity: 1. Measured by its binding ability in a functional ELISA. Immobilized human IL-33 at 10 μg/ml (100 μl/well) can bind human IL1RL1 with a linear range of 0.31-5 ng/ml.
  2. Measured in a cell proliferation assay using D10.G4.1 mouse helper T cells costimulated with anti-CD3. The ED50 for this effect is typically 0.15-0.6 ng/mL.
• Molecular Mass: The recombinant human IL33 comprises 160 amino acids and predicts a molecular mass of 18 kDa as estimated in SDS-PAGE under reducing conditions.
• Purity: > 98 % as determined by SDS-PAGE
• Stability: Samples are stable for up to twelve months from date of receipt at -70 centigrade
• Storage: Store it under sterile conditions at -20centigrade to -80 centigrade. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

Gene Information

• Gene Name: IL33 interleukin 33 [ Homo sapiens ]
• Official Symbol: IL33
• Synonyms: IL33; interleukin 33; C9orf26, chromosome 9 open reading frame 26 (NF HEV); interleukin-33; DKFZp586H0523; DVS27; DVS27 related protein; IL1F11; interleukin 1 family; member 11; NF HEV; nuclear factor for high endothelial venules; IL-33; IL-1F11; DVS27-related protein; interleukin-1 family member 11; nuclear factor from high endothelial venules; NF-HEV; NFEHEV; C9orf26; RP11-575C20.2
• Gene ID: 90865
• mRNA Refseq: NM_033439
• Protein Refseq: NP_254274
• MIM: 608678
• UniProt ID: O95760
• Chromosome Location: 9p24.1
• Pathway: Cytosolic DNA-sensing pathway, organism-specific biosystem; Cytosolic DNA-sensing pathway, conserved biosystem; Influenza A, organism-specific biosystem; Influenza A, conserved biosystem
• Function: cytokine activity; protein binding

Reviews

10/16/2021

Good solubility and is easy to operate and purify.

05/03/2021

Effectively mimics the function of the target protein in vitro.

03/18/2020

IL33 has a wide range of applications in the field of scientific research and is suitable for a variety of experimental design and research purposes.

Q&As

Which immune cells can recombinant IL33 be used to detect?

It can be used to detect immune cells such as macrophages and dendritic cells.

In what research fields can recombinant IL33 be applied?

This protein applied in immunology, drug research, life science and other fields.

What is the action mechanism of IL33?

Regulates the activity of immune cells by binding to receptors to stimulate the production of inflammatory factors such as interferon and TNF-α.

Besides treating asthma and hay fever, what other diseases can be treated with IL33?

IL33 can also be used to treat a variety of inflammatory diseases, such as inflammatory bowel disease, psoriasis and so on.

How to prepare IL33?

The preparation of IL33 requires first cloning the IL33 gene into the expression vector, and then the expression vector is expressed and purified in the cell culture medium.

How long does it take to treat asthma with IL33?

Treating asthma with recombinant IL33 takes several weeks to several months to be effective, depending on the severity of the condition and the individual patient.